Paris/Hyderabad, Oct 31: A new agreement by Unitaid, the Global Fund and Sanofi will drastically lower the price of rifapentine, a critically important drug used to prevent tuberculosis (TB), it was announced on Thursday at the 50th Union World Conference on Lung Health taking place this week in Hyderabad, India.
The conference is convened by the International Union Against Tuberculosis and Lung Disease (The Union).
According to a statement, the agreement with Sanofi brings rifapentine (Priftin®) 150mg tablets down from €13.60/pack of 24 tablets to a price of €4.62/pack of 24 tablets, a 66 percent discount. (One Euro= Rs 83 approx) The discounted price will be available to the public sectors of low-income countries, lower-middle income countries, and upper-middle-income countries with a high burden of TB and TB-HIV.
It comes on the back of promising Phase IIb results of the M72 TB vaccine candidate reported by pharmaceutical company GSK and the International AIDS Vaccine Initiative (IAVI) earlier this week at the TBScience pre-conference event.
Today’s official press conference on prevention also revealed that US-based National Institutes of Health will launch a Phase III multidrug-resistant TB (MDR-TB) prevention trial (Phoenix) in 12 high burden countries including India (Chennai and Pune) and that the final results of The Union’s TITI study point to a new model of pediatric TB prevention efforts. (UNI)